在过敏原免疫疗法 (AIT) 选择中共享决策,使用呼吸道过敏患者的问卷:德尔菲共识研究
Mónica Antón1, Nieves Cabañes2, Salvador Fernández-Meléndez3
1Allergy Department, Hospital Universitario San Juan de Alicante, Alicante, Spain.
一份经过验证的问卷帮助过敏学家客观地评估患者对过敏原免疫治疗 (AIT) 的偏好. 该工具有助于为每个人选择最佳的AIT选项,改善治疗决策.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 临床实践指南 临床实践指南
- 以患者为中心的护理
背景情况:
- 过敏原免疫疗法 (AIT) 是对过敏疾病的关键治疗方法.
- 评估患者的偏好对于成功的AIT遵守和结果至关重要.
- 目前在AIT中评估患者偏好的方法可能缺乏客观性.
研究的目的:
- 开发和验证一个针对过敏学家的问卷.
- 客观地评估患者对过敏原免疫治疗 (AIT) 的偏好.
- 帮助临床医生选择最适合患者的AIT选项.
主要方法:
- 一个德尔菲的共识过程,涉及15位过敏学家和200名小组成员.
- 使用了9点利克特级别的16项调查问卷.
- 共识被定义为小组成员之间≥66.6%的同意或不同意.
主要成果:
- 在200名专家中,有195名专家 (97.5%) 参与.
- 在16个项目中有12个项目达成共识 (75%).
- 验证问题涵盖患者的知识,坚持障碍,行为,未来的行动,成本和偏好.
结论:
- 现在可以使用12个问题,德尔菲验证的问卷.
- 调查问卷有助于客观地评估患者对AIT的偏好.
- 它支持过敏科医生做出明智,无条件的AIT治疗决策.
更多相关视频
03:40Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
相关概念视频
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-I: Introduction
Asthma-IV: Nursing Management
First, in...
Asthma-III: Symptoms and Complications
Classification of Asthma
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
